Cargando…

组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展

Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143971/
https://www.ncbi.nlm.nih.gov/pubmed/33819971
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.11
_version_ 1783696864978141184
collection PubMed
description Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of immunotherapy in cancer patients. Histone deacetylase inhibitor (HDACi), as a class of epigenetic regulatory drugs, plays an important role in regulating cell cycle, proliferation, differentiation, and activity. In recent years, Studies have found that HDACi can not only regulate cell biological characteristics, but also closely related to the improvement of tumor ICIs drug resistance. Therefore, the study on how HDACi enhances the efficacy of ICIs is of great significance to tumor immunotherapy. This article will review the research progress of HDACi combined with ICIs in treating malignant tumors and their related mechanism.
format Online
Article
Text
id pubmed-8143971
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-81439712021-05-26 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 Zhongguo Fei Ai Za Zhi 综述 Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of immunotherapy in cancer patients. Histone deacetylase inhibitor (HDACi), as a class of epigenetic regulatory drugs, plays an important role in regulating cell cycle, proliferation, differentiation, and activity. In recent years, Studies have found that HDACi can not only regulate cell biological characteristics, but also closely related to the improvement of tumor ICIs drug resistance. Therefore, the study on how HDACi enhances the efficacy of ICIs is of great significance to tumor immunotherapy. This article will review the research progress of HDACi combined with ICIs in treating malignant tumors and their related mechanism. 中国肺癌杂志编辑部 2021-03-20 /pmc/articles/PMC8143971/ /pubmed/33819971 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.11 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https: //creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) .
spellingShingle 综述
组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
title 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
title_full 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
title_fullStr 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
title_full_unstemmed 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
title_short 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
title_sort 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143971/
https://www.ncbi.nlm.nih.gov/pubmed/33819971
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.11
work_keys_str_mv AT zǔdànbáiqùyǐxiānhuàméiyìzhìjìliánhémiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhǒngliúdeyánjiūjìnzhǎn
AT zǔdànbáiqùyǐxiānhuàméiyìzhìjìliánhémiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhǒngliúdeyánjiūjìnzhǎn
AT zǔdànbáiqùyǐxiānhuàméiyìzhìjìliánhémiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhǒngliúdeyánjiūjìnzhǎn